Cytoplasmic poly(A)-binding protein 1 (PABPC1) is a prognostic biomarker to predict survival in nasopharyngeal carcinoma regardless of chemoradiotherapy

BMC Cancer

Research

Shengen Xu¹  Xiaochen Li²  Xingwang Sun²  Feng Ling²  Wenbo Long² 

[1] Department of Otorhinolaryngology-Head and Neck Surgery, the Affiliated Hospital of Southwest Medical University, Sichuan, People’s Republic of China;Pathology Department of the First Affiliated Hospital, Southwest Medical University, Sichuan, People’s Republic of China;

关键词: Nasopharyngeal carcinoma;    Molecular marker;    Epstein-Barr virus;    Overall survival;    Disease-free survival;    Induction;    Concurrent chemotherapy;    Intensity-modulated radiotherapy;   

DOI  :  10.1186/s12885-023-10629-4

 received in 2022-08-02, accepted in 2023-02-10,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundNasopharyngeal carcinoma (NPC), especially the nonkeratinizing type, is a malignant tumor primarily occurring in southern China and Southeast Asia. Chemotherapy (CT) and combined radiotherapy (RT) is used to treat NPC. However, the mortality rate is high in recurrent and metastatic NPC. We developed a molecular marker, analyzed its correlation with clinical characteristics, and assessed the prognostic value among NPC patients with or without chemoradiotherapy.MethodsA total of 157 NPC patients were included in this study, with 120 undergoing treatment and 37 without treatment. EBER1/2 expression was investigated using in situ hybridization (ISH). Expression of PABPC1, Ki-67, and p53 was detected with immunohistochemistry. The correlations of EBER1/2 and the expression of the three proteins having clinical features and prognosis were evaluated.ResultsThe expression of PABPC1 was associated with age, recurrence, and treatment but not with gender, TNM classification, or the expression of Ki-67, p53, or EBER. High expression of PABPC1 was associated with poor overall survival (OS) and disease-free survival (DFS) and was an independent predictor depending on multivariate analysis. Comparatively, no significant correlation was observed between the expression of p53, Ki-67, and EBER and survival. In this study, 120 patients received treatments and revealed significantly better OS and DFS than the untreated 37 patients. PABPC1 high expression was an independent predictor of shorter OS in the treated (HR = 4.012 (1.238–13.522), 95% CI, p = 0.021) and the untreated groups (HR = 5.473 (1.051–28.508), 95% CI, p = 0.044). However, it was not an independent predictor of shorter DFS in either the treated or the untreated groups. No significant survival difference was observed between patients with docetaxel-based induction chemotherapy (IC) + concurrent chemoradiotherapy (CCRT) and those with paclitaxel-based IC + CCRT. However, when combined with treatment and PABPC1 expression, patients with paclitaxel-added chemoradiotherapy plus PABPC1 low expression had significantly better OS than those who underwent chemoradiotherapy (p = 0.036).ConclusionsHigh expression of PABPC1 is associated with poorer OS and DFS among NPC patients. Patients with PABPC1 having low expression revealed good survival irrespective of the treatment received, indicating that PABPC1 could be a potential biomarker for triaging NPC patients.

【 授权许可】

CC BY   
© The Author(s) 2023. corrected publication 2023

【 图 表 】

Fig. 6

Fig. 8

Fig. 5